{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:42:30Z","timestamp":1779208950285,"version":"3.51.4"},"reference-count":44,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Introduction: Antiphospholipid syndrome (APS) is an autoimmune prothrombotic disorder associated with both venous and arterial thrombosis, most notably ischemic stroke. Patients face a high risk of recurrence, and yet optimal strategies for secondary prevention remain uncertain. Methods: We conducted a narrative review of the literature on secondary prevention of ischemic stroke in APS. We performed a comprehensive literature search of PubMed for English-language articles on secondary stroke prevention in APS. Studies were included if they were original human research (e.g., randomized trials, cohort, or case\u2013control studies) or relevant reviews addressing APS-related stroke prevention. Results: Vitamin K antagonists (VKAs) remain the standard of care for high-risk patients with arterial events. Several randomized controlled trials demonstrated higher recurrence rates, particularly of stroke, among APS patients treated with direct oral anticoagulants (DOACs). The optimal target INR remains debated; pooled analyses suggest no clear advantage of high-intensity anticoagulation (INR 3\u20134) over standard-intensity (INR 2\u20133), but individualized adjustment is warranted in select cases. In patients with recurrence despite adequate anticoagulation, adding an antiplatelet agent may be beneficial, although supporting evidence is limited. Adjunctive statin therapy shows promise in reducing endothelial dysfunction and prothrombotic markers, with observational data suggesting a possible protective effect, although randomized evidence is lacking. In addition, patent foramen ovale (PFO) closure has been proposed in selected APS patients with paradoxical embolisms, particularly when combined with anticoagulation. Non-pharmacological strategies, including structured lifestyle modification and rigorous vascular risk-factor management, are strongly recommended, as traditional cardiovascular risk factors synergistically increase recurrence risk. Conclusions: Secondary prevention of ischemic stroke in APS requires an individualized approach. VKAs remain first-line, with consideration of antiplatelet add-on, statins, lifestyle interventions, and PFO closure in appropriate settings. Future well-designed clinical trials are needed to refine INR targets, validate combination strategies, and clarify the role of adjunctive therapies in this complex patient population.<\/jats:p>","DOI":"10.3390\/jcm14228026","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T16:46:22Z","timestamp":1763138782000},"page":"8026","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Secondary Prevention Strategies for Ischemic Stroke in Antiphospholipid Syndrome"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2251-8663","authenticated-orcid":false,"given":"Jonathan","family":"Naftali","sequence":"first","affiliation":[{"name":"Department of Neurology, Rabin Medical Center, Zeev Jabotinsky St. 39, Petah Tikva 4941492, Israel"},{"name":"Faculty of Medicine, Tel Aviv University, Tel-Aviv 69978, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2375-5551","authenticated-orcid":false,"given":"Sheree","family":"Finkelshtain","sequence":"additional","affiliation":[{"name":"Department of Neurology, Rabin Medical Center, Zeev Jabotinsky St. 39, Petah Tikva 4941492, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eitan","family":"Auriel","sequence":"additional","affiliation":[{"name":"Department of Neurology, Rabin Medical Center, Zeev Jabotinsky St. 39, Petah Tikva 4941492, Israel"},{"name":"Faculty of Medicine, Tel Aviv University, Tel-Aviv 69978, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and Management of the Antiphospholipid Syndrome","volume":"378","author":"Garcia","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1177\/0961203309106832","article-title":"The Euro-Phospholipid project: Epidemiology of the antiphospholipid syndrome in Europe","volume":"18","author":"Cervera","year":"2009","journal-title":"Lupus"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11926-021-01038-2","article-title":"Epidemiology of Antiphospholipid Syndrome in the General Population","volume":"23","author":"Dabit","year":"2022","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/17474930221150349","article-title":"Antiphospholipid syndrome, antiphospholipid antibodies, and stroke","volume":"18","author":"Mittal","year":"2023","journal-title":"Int. J. Stroke"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/17474930241293236","article-title":"Significance of Cerebral Microinfarcts in Antiphospholipid Syndrome: A population-based study","volume":"20","author":"Naftali","year":"2025","journal-title":"Int. J. Stroke"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR Antiphospholipid Syndrome Classification Criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1111\/jth.14935","article-title":"Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis","volume":"18","author":"Zuily","year":"2020","journal-title":"J. Thromb. Haemost. JTH"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1177\/23969873241247978","article-title":"European Stroke Organisation (ESO) Guidelines on the diagnosis and management of patent foramen ovale (PFO) after stroke","volume":"9","author":"Caso","year":"2024","journal-title":"Eur. Stroke J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): A randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs. warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: A randomized trial","volume":"6","author":"Woller","year":"2022","journal-title":"Blood Adv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/FJC.0000000000001578","article-title":"Apixaban Versus Vitamin K Antagonists in Patients with Antiphospholipid Syndrome: A Cohort Study","volume":"84","author":"Sikorska","year":"2024","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial","volume":"171","author":"Vidal","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"ref_15","first-page":"17006","article-title":"Direct oral anticoagulants vs. vitamin K antagonists in patients with single- or double-positive antiphospholipid syndrome: A systematic review and meta-analysis","volume":"135","author":"Nicoletto","year":"2025","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1056\/NEJMoa035241","article-title":"A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome","volume":"349","author":"Crowther","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1538-7836.2005.01340.x","article-title":"A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)","volume":"3","author":"Finazzi","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.7326\/0003-4819-117-4-303","article-title":"Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients","volume":"117","author":"Rosove","year":"1992","journal-title":"Ann. Intern. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJM199504133321504","article-title":"The management of thrombosis in the antiphospholipid-antibody syndrome","volume":"332","author":"Khamashta","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct Oral Anticoagulants vs. Vitamin K Antagonists in Patients with Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/MBC.0000000000001153","article-title":"Comparing the efficacy and safety of direct oral anticoagulants versus Vitamin K antagonists in patients with antiphospholipid syndrome: A systematic review and meta-analysis","volume":"33","author":"Wu","year":"2022","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_22","first-page":"15","article-title":"Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome","volume":"7","author":"Okuma","year":"2009","journal-title":"Int. J. Med. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1182\/bloodadvances.2017008185","article-title":"Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy","volume":"1","author":"Jackson","year":"2017","journal-title":"Blood Adv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/rheumatology\/key340","article-title":"Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndrome","volume":"58","author":"Ohnishi","year":"2019","journal-title":"Rheumatology"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Yang, W., Chung, M., Ha, J., Kang, D.-W., Lee, E.-J., Jeong, H.-Y., Kim, J.-M., Jung, K.-H., and Lee, S.-H. (2025). Secondary prevention with antiplatelet medications in patients with antiphospholipid antibody-related stroke. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-91739-w"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Attachaipanich, T., Aungsusiripong, A., Piriyakhuntorn, P., Hantrakool, S., Rattarittamrong, E., Rattanathammethee, T., Tantiworawit, A., Norasetthada, L., and Chai-Adisaksopha, C. (2023). Antithrombotic therapy in antiphospholipid syndrome with arterial thrombosis: A systematic review and network meta-analysis. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1196800"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/bjh.19635","article-title":"Guidelines on the investigation and management of antiphospholipid syndrome","volume":"205","author":"Arachchillage","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1093\/rheumatology\/keab410","article-title":"Effect of statins on the prevention of recurrent thrombosis in thrombotic antiphospholipid syndrome","volume":"61","author":"Kwon","year":"2022","journal-title":"Rheumatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/annrheumdis-2013-203622","article-title":"A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients","volume":"73","author":"Erkan","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1159\/000512184","article-title":"Patent Foramen Ovale Closure among Patients with Hypercoagulable States Maintained on Antithrombotic Therapy","volume":"146","author":"Buber","year":"2021","journal-title":"Cardiology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1016\/j.jcin.2020.09.059","article-title":"Patent Foramen Ovale Attributable Cryptogenic Embolism with Thrombophilia Has Higher Risk for Recurrence and Responds to Closure","volume":"13","author":"Liu","year":"2020","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.jcin.2023.04.027","article-title":"Short- and Long-Term Outcomes in Patients with Thrombophilia Undergoing Transcatheter Closure of Patent Foramen Ovale","volume":"16","author":"Abrahamyan","year":"2023","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jns.2017.04.014","article-title":"Clinical outcomes and a high prevalence of abnormalities on comprehensive arterial and venous thrombophilia screening in TIA or ischaemic stroke patients with a patent foramen ovale, an inter-atrial septal aneurysm or both","volume":"377","author":"Lim","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1212\/WNL.0000000000009294","article-title":"Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology","volume":"94","author":"Gronseth","year":"2020","journal-title":"Neurology"},{"key":"ref_35","first-page":"100039","article-title":"SCAI Guidelines for the Management of Patent Foramen Ovale","volume":"1","author":"Kavinsky","year":"2022","journal-title":"J. Soc. Cardiovasc. Angiogr. Interv."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/rheumatology\/41.8.924","article-title":"A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome","volume":"41","author":"Erkan","year":"2002","journal-title":"Rheumatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1134\/S1607672925700152","article-title":"Thrombotic Antiphospholipid Syndrome: Recurrent Thromboses","volume":"522","author":"Reshetnyak","year":"2025","journal-title":"Dokl. Biochem. Biophys."},{"key":"ref_38","first-page":"2018","article-title":"Risk factors associated with thrombosis in patients with antiphospholipid antibodies","volume":"28","author":"Hansen","year":"2001","journal-title":"J. Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"475","DOI":"10.37349\/ei.2023.00114","article-title":"Risk factors and recurrent thrombosis in primary antiphospholipid syndrome","volume":"3","author":"Cheldieva","year":"2023","journal-title":"Explor. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Schulz, A., Herrmann, E., Ott, O., and Lindhoff-Last, E. (2022). Thromboembolic Antiphospholipid Syndrome (APS): Efficacy and Safety of Different Anticoagulants-Results of the APSantiCO Registry. J. Clin. Med., 11.","DOI":"10.3390\/jcm11164845"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/annrheumdis-2015-eular.6125","article-title":"Antiphospholipid Antibodies Profile and Thrombosis Recurrence (AB0572)","volume":"74","author":"Medina","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1468-1331.2001.00180.x","article-title":"Ischemic stroke of unusual cause: Clinical features, etiology and outcome","volume":"8","author":"Arboix","year":"2001","journal-title":"Eur. J. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000535644","article-title":"D-Dimer Trends Predict Recurrent Stroke in Patients with Cancer-Related Hypercoagulability","volume":"14","author":"Fujinami","year":"2023","journal-title":"Cerebrovasc. Dis. Extra"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejim.2022.06.023","article-title":"Epidemiology of subclinical atrial fibrillation in patients with cardiac implantable electronic devices: A systematic review and meta-regression","volume":"103","author":"Proietti","year":"2022","journal-title":"Eur. J. Intern. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/22\/8026\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T16:56:52Z","timestamp":1763139412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/22\/8026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":44,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["jcm14228026"],"URL":"https:\/\/doi.org\/10.3390\/jcm14228026","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]}}}